About FDA

Office of Surveillance and Epidemiology (OSE)

(Formerly the Office of Drug Safety)


CDER evaluates the safety profiles of drugs available to American consumers using a variety of tools and disciplines throughout the life cycle of the drugs. We maintain a system of postmarketing surveillance and risk assessment programs to identify adverse events that did not appear during the drug development process. We learn about adverse events through required reporting by companies and through voluntary reports submitted to FDA’s MedWatch program, which totals more than 1 million reports per year. Staff in the Office of Surveillance and Epidemiology use this information to identify drug safety concerns and recommend actions to improve product safety and protect the public health.

Activities include

  • updating drug labeling
  • providing more information to the community
  • implementing or revising a risk management program
  • on rare occasions, reevaluating approval or marketing decisions

CDER also works with drug companies to reduce medication errors related to confusing labels, labeling, drug packaging, and drug names that look alike or sound alike.

How to Contact Us 

Please feel free to send comments or questions to Contact CDER

Back to Top

Related Resources

Page Last Updated: 04/24/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English